Skip to main content

Table 3 Association of antiplatelet medications and risk of death

From: Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma

  HR 95% CI p-value
Antiplatelet No Yes  
Unadjusted 1.0 0.73 (0.58-0.92) 0.0008
Adjusted* 1.0 0.76 (0.58-0.99) 0.04
Antiplatelet medications in 5 categories of platelet counts
Low 1.0 1.74 (0.74-4.09) 0.20
Low Normal 1.0 0.88 (0.55-1.42) 0.58
Mid Normal 1.0 0.68 (0.42-1.11) 0.12
High normal 1.0 0.87(0.48-1.51) 0.64
High 1.0 0.42 (0.17-1.05) 0.06
  1. *Adjusted for age, race, tumor site, grade, treatment, platelet count and smoking.